检验医学 ›› 2016, Vol. 31 ›› Issue (10): 835-843.DOI: 10.3969/j.issn.1673-8640.2016.010.001
• 论坛 • 下一篇
林铖1, 姜傥2
收稿日期:
2016-08-04
出版日期:
2016-10-20
发布日期:
2016-11-01
作者简介:
null作者简介:林 铖,男,1988年生,博士,主管技师,主要从事肿瘤的诊断及伴随诊断领域的基因研究。
通讯作者:姜 傥,联系电话:0571-56137803。
LIN Cheng1, JIANG Tang2
Received:
2016-08-04
Online:
2016-10-20
Published:
2016-11-01
摘要:
作为非小细胞肺癌治疗史上的里程碑,表皮生长因子受体(EGFR)-酪氨酸激酶抑制剂(TKI)的出现显著延长了非小细胞肺癌患者的生存期,改善了患者的生存质量。亚洲的非小细胞肺癌患者EGFR基因的突变频率远高于白种人,将更加受益于EGFR-TKI药物。然而,分子靶向药物面临的一个重要问题就是耐药。这些最初受益于EGFR-TKI药物的患者,其肿瘤最终都将再次发生进展,并且这种状况往往发生在开始用药后1年左右。由于EGFR-TKI的继发耐药,目前已相继出现了3代EGFR-TKI药物。在众多耐药机制中最受关注的耐药突变就是EGFR T790M和C797S点突变。为了达到更好的治疗效果,必须对使用EGFR-TKI药物的患者进行继发耐药动态监测。组织活检是癌症诊断的金标准,然而组织活检由于存在操作风险较高、组织样本获得困难、无法实时检测及肿瘤异质性等问题,无法对非小细胞肺癌患者进行动态监测。液体活检是一种方便、快捷、具有较高可靠性、新兴的非侵入性检测方法,其通过检测血液中循环肿瘤细胞(CTC)、循环肿瘤DNA(ctDNA)及肿瘤释放出的外泌体,对肿瘤进行早期诊断、筛查、疗效和预后评估以及耐药监测等。文章综述了EGFR-TKI药物及液体活检技术的发展现状,并对液体活检技术在非小细胞肺癌患者EGFR-TKI继发耐药中的应用进行简评和展望。
中图分类号:
林铖, 姜傥. 液体活检技术在非小细胞肺癌患者EGFR-TKI继发耐药中的应用[J]. 检验医学, 2016, 31(10): 835-843.
LIN Cheng, JIANG Tang. Liquid biopsy for monitoring EGFR-TKI drug resistance in patients with non-small-cell lung cancer[J]. Laboratory Medicine, 2016, 31(10): 835-843.
[1] | SIEGEL RL,MILLER KD,JEMAL A.Cancer statistics,2016[J]. CA Cancer J Clin,2016,66(1):7-30. |
[2] | CHEN W,ZHENG R,BAADE PD,et al.Cancer statistics in China,2015[J]. CA Cancer J Clin,2016,66(2):115-132. |
[3] | BUYUKCELIK A,YALCIN B,UTKAN G.Multidisciplinary management of lung cancer[J]. N Engl J Med,2004,350(19):2008-2010. |
[4] | JEMAL A,BRAY F,CENTER MM,et al.Global cancer statistics[J]. CA Cancer J Clin,2011,61(2):69-90. |
[5] | GHARWAN H,GRONINGER H.Kinase inhibitors and monoclonal antibodies in oncology:clinical implications[J]. Nat Rev Clin Oncol,2016,13(4):209-227. |
[6] | PAO W,GIRARD N.New driver mutations in non-small-cell lung cancer[J]. Lancet Oncol,2011,12(2):175-180. |
[7] | KOHNO T,ICHIKAWA H,TOTOKI Y,et al.KIF5B-RET fusions in lung adenocarcinoma[J]. Nat Med,2012,18(3):375-377. |
[8] | ZAPPA C,MOUSA SA.Non-small cell lung cancer:current treatment and future advances[J]. Transl Lung Cancer Res,2016,5(3):288-300. |
[9] | SCHILLER JH,HARRINGTON D,BELANI CP,et al.Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer[J]. N Engl J Med,2002,346(2):92-98. |
[10] | SCAGLIOTTI GV,PARIKH P,VON PAWEL J,et al.Phase Ⅲ study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer[J] . J Clin Oncol,2008,26(21):3543-3551. |
[11] | MITSUDOMI T,MORITA S,YATABE Y,et al.Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405):an open label,randomised phase 3 trial[J]. Lancet Oncol,2010,11(2):121-128. |
[12] | SHARMA SV,BELL DW,SETTLEMAN J,et al.Epidermal growth factor receptor mutations in lung cancer[J]. Nat Rev Cancer,2007,7(3):169-181. |
[13] | LYNCH TJ,BELL DW,SORDELLA R,et al.Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib[J]. N Engl J Med,2004,350(21):2129-2139. |
[14] | ZHANG X,GUREASKO J,SHEN K,et al.An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor[J]. Cell,2006,125(6):1137-1149. |
[15] | PAO W,CHMIELECKI J.Rational,biologically based treatment of EGFR-mutant non-small-cell lung cancer[J]. Nat Rev Cancer,2010,10(11):760-774. |
[16] | KUMAR A,PETRI ET,HALMOS B,et al.Structure and clinical relevance of the epidermal growth factor receptor in human cancer[J]. J Clin Oncol,2008,26(10):1742-1751. |
[17] | SHIAU CJ,BABWAH JP,DA CUNHA SANTOS G,et al. Sample features associated with success rates in population-based EGFR mutation testing[J]. J Thorac Oncol,2014,9(7):947-956. |
[18] | BRUGGER W,THOMAS M.EGFR-TKI resistant non-small cell lung cancer (NSCLC):new developments and implications for future treatment[J]. Lung Cancer,2012 ,77(1):2-8. |
[19] | COSTA DB,KOBAYASHI SS.Whacking a mole-cule:clinical activity and mechanisms of resistance to third generation EGFR inhibitors in EGFR mutated lung cancers with EGFR-T790M[J]. Transl Lung Cancer Res,2015,4(6):809-815. |
[20] | KE EE,ZHOU Q,WU YL.Emerging paradigms in targeted treatments for Asian patients with NSCLC[J]. Expert Opin Pharmacother,2015,16(8):1167-1176. |
[21] | METRO G,CRINÒ L.Advances on EGFR mutation for lung cancer[J]. Transl Lung Cancer Res,2012,1(1):5-13. |
[22] | LANDI L,CAPPUZZO F.Pharmacotherapy targeting the EGFR oncogene in NSCLC[J]. Expert Opin Pharmacother,2014,15(16):2293-2305. |
[23] | MILLER VA,HIRSH V,CADRANEL J,et al.Afatinib versus placebo for patients with advanced,metastatic non-small-cell lung cancer after failure of erlotinib,gefitinib,or both,and one or two lines of chemotherapy (LUX-Lung 1):a phase 2b/3 randomised trial[J]. Lancet Oncol,2012,13(5):528-538. |
[24] | CROSS DA,ASHTON SE,GHIORGHIU S,et al.AZD9291,an irreversible EGFR TKI,overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer[J]. Cancer Discov,2014,4(9):1046-1061. |
[25] | JA(··)NNE PA,YANG JC,KIM DW,et al. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer[J]. N Engl J Med,2015,372(18):1689-1699. |
[26] | THRESS KS,PAWELETZ CP,FELIP E,et al.Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M[J]. Nat Med,2015,21(6):560-562. |
[27] | YU HA,TIAN SK,DRILON AE,et al.Acquired resistance of EGFR-mutant lung cancer to a T790M-specific EGFR inhibitor:emergence of a third mutation (C797S) in the EGFR tyrosine kinase domain[J]. JAMA Oncol,2015,1(7):982-984. |
[28] | JIA Y,YUN CH,PARK E,et al.Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors[J]. Nature,2016,534(7605):129-132. |
[29] | ALIX-PANABIÈRES C,PANTEL K. Circulating tumor cells:liquid biopsy of cancer[J]. Clin Chem,2013,59(1):110-118. |
[30] | ESPOSITO A,BARDELLI A,CRISCITIELLO C,et al.Monitoring tumor-derived cell-free DNA in patients with solid tumors:clinical perspectives and research opportunities[J]. Cancer Treat Rev,2014,40(5):648-655. |
[31] | GIALLOMBARDO M,CHACÁRTEGUI BORRÁS J,CASTIGLIA M,et al. Exosomal miRNA analysis in non-small cell lung cancer (NSCLC) patients' plasma through qPCR:a feasible liquid biopsy tool[J]. J Vis Exp,2016,doi:10.3791/53900. |
[32] | ISOBE K,HATA Y,KOBAYASHI K,et al.Clinical significance of circulating tumor cells and free DNA in non-small cell lung cancer[J]. Anticancer Res,2012,32(8):3339-3344. |
[33] | ASHWORTH TR. A case of cancer in which cells similar to those in the tumors were seen in the blood after death[J]. Aus Med J,1869,14:146-149. |
[34] | FRIEL AM,CORCORAN C,CROWN J,et al.Relevance of circulating tumor cells,extracellular nucleic acids,and exosomes in breast cancer[J]. Breast Cancer Res Treat,2010,123(3):613-625. |
[35] | FIDLER IJ.The pathogenesis of cancer metastasis:the 'seed and soil' hypothesis revisited[J]. Nat Rev Cancer,2003,3(6):453-458. |
[36] | THIERY JP,LIM CT.Tumor dissemination:an EMT affair[J]. Cancer Cell,2013,23(3):272-273. |
[37] | HOU JM,KREBS MG,LANCASHIRE L,et al.Clinical significance and molecular characteristics of circulating tumor cells and circulating tumor microemboli in patients with small-cell lung cancer[J]. J Clin Oncol ,2012,30(5):525-532. |
[38] | ALLAN AL,KEENEY M.Circulating tumor cell analysis:technical and statistical considerations for application to the clinic[J]. J Oncol,2010,2010:426218. |
[39] | KREBS MG,METCALF RL,CARTER L,et al.Molecular analysis of circulating tumour cells-biology and biomarkers[J]. Nat Rev Clin Oncol,2014,11(3):129-144. |
[40] | PARKINSON DR,DRACOPOLI N,PETTY BG,et al.Considerations in the development of circulating tumor cell technology for clinical use[J]. J Transl Med,2012,10:138. |
[41] | ALIX-PANABIÈRES C,PANTEL K. Technologies for detection of circulating tumor cells:facts and vision[J]. Lab Chip,2014,14(1):57-62. |
[42] | HAROUAKA R,KANG Z,ZHENG SY,et al.Circulating tumor cells:advances in isolation and analysis,and challenges for clinical applications[J]. Pharmacol Ther,2014,141(2):209-221. |
[43] | JIN C,MCFAUL SM,DUFFY SP,et al.Technologies for label-free separation of circulating tumor cells:from historical foundations to recent developments[J]. Lab Chip,2014,14(1):32-44. |
[44] | ALIX-PANABIÈRES C,PANTEL K. Challenges in circulating tumour cell research[J]. Nat Rev Cancer,2014,14(9):623-631. |
[45] | RAO C,BUI T,CONNELLY M,et al.Circulating melanoma cells and survival in metastatic melanoma[J]. Int J Oncol,2011,38(3):755-760. |
[46] | NICHOLS AC,LOWES LE,SZETO CC,et al.Detection of circulating tumor cells in advanced head and neck cancer using the CellSearch system[J]. Head Neck,2012,34(10):1440-1444. |
[47] | DE BONO JS,SCHER HI,MONTGOMERY RB,et al.Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer[J]. Clin Cancer Res,2008,14(19):6302-6309. |
[48] | DE BONO JS,LOGOTHETIS CJ,MOLINA A,et al.Abiraterone and increased survival in metastatic prostate cancer[J]. N Engl J Med,2011,364(21):1995-2005. |
[49] | KREBS MG,SLOANE R,PRIEST L,et al.Evaluation and prognostic significance of circulating tumor cells in patients with non-small-cell lung cancer[J]. J Clin Oncol,2011,29(12):1556-1563. |
[50] | HOFMAN V,BONNETAUD C,ILIE MI,et al.Preoperative circulating tumor cell detection using the isolation by size of epithelial tumor cell method for patients with lung cancer is a new prognostic biomarker[J]. Clin Cancer Res,2011,17(4):827-835. |
[51] | HOFMAN V,ILIE MI,LONG E,et al.Detection of circulating tumor cells as a prognostic factor in patients undergoing radical surgery for non-small-cell lung carcinoma:comparison of the efficacy of the CellSearch AssayTM and the isolation by size of epithelial tumor cell method[J]. Int J Cancer,2011,129(7):1651-1660. |
[52] | MAHESWARAN S,SEQUIST LV,NAGRATH S,et al.Detection of mutations in EGFR in circulating lung-cancer cells[J]. N Engl J Med,2008,359(4):366-377. |
[53] | SUNDARESAN TK,SEQUIST LV,HEYMACH JV,et al.Detection of T790M,the acquired resistance EGFR mutation,by tumor biopsy versus noninvasive blood-based analyses[J]. Clin Cancer Res,2016,22(5):1103-1110. |
[54] | RAN R,LI L,WANG M,et al.Determination of EGFR mutations in single cells microdissected from enriched lung tumor cells in peripheral blood[J]. Anal Bioanal Chem,2013,405(23):7377-7382. |
[55] | LEON SA,SHAPIRO B,SKLAROFF DM,et al.Free DNA in the serum of cancer patients and the effect of therapy[J]. Cancer Res,1977,37(3):646-650. |
[56] | STROUN M,ANKER P,MAURICE P,et al.Neoplastic characteristics of the DNA found in the plasma of cancer patients[J]. Oncology,1989,46(5):318-322. |
[57] | JAHR S,HENTZE H,ENGLISCH S,et al.DNA fragments in the blood plasma of cancer patients:quantitations and evidence for their origin from apoptotic and necrotic cells[J]. Cancer Res,2001,61(4):1659-1665. |
[58] | DIEHL F,SCHMIDT K,CHOTI MA,et al.Circulating mutant DNA to assess tumor dynamics[J]. Nat Med,2008,14(9):985-990. |
[59] | YU SC,LEE SW,JIANG P,et al.High-resolution profiling of fetal DNA clearance from maternal plasma by massively parallel sequencing[J]. Clin Chem,2013,59(8):1228-1237. |
[60] | MOULIERE F,EL MESSAOUDI S,PANG D,et al.Multi-marker analysis of circulating cell-free DNA toward personalized medicine for colorectal cancer[J]. Mol Oncol,2014,8(5):927-941. |
[61] | SOZZI G,CONTE D,LEON M,et al.Quantification of free circulating DNA as a diagnostic marker in lung cancer[J]. J Clin Oncol,2003,21(21):3902-3908. |
[62] | KIM K,SHIN DG,PARK MK,et al.Circulating cell-free DNA as a promising biomarker in patients with gastric cancer:diagnostic validity and significant reduction of cfDNA after surgical resection[J]. Ann Surg Treat Res,2014,86(3):136-142. |
[63] | WANG JY,HSIEH JS,CHANG MY,et al.Molecular detection of APC,K-ras,and p53 mutations in the serum of colorectal cancer patients as circulating biomarkers[J]. World J Surg,2004,28(7):721-726. |
[64] | FUJIWARA K,FUJIMOTO N,TABATA M,et al.Identification of epigenetic aberrant promoter methylation in serum DNA is useful for early detection of lung cancer[J]. Clin Cancer Res,2005,11(3):1219-1225. |
[65] | TANIGUCHI K,UCHIDA J,NISHINO K,et al.Quantitative detection of EGFR mutations in circulating tumor DNA derived from lung adenocarcinomas[J]. Clin Cancer Res,2011,17(24):7808-7815. |
[66] | ZHENG D,YE X,ZHANG MZ,et al.Plasma EGFR T790M ctDNA status is associated with clinical outcome in advanced NSCLC patients with acquired EGFR-TKI resistance[J]. Sci Rep,2016,6:20913. |
[67] | YANAGITA M,REDIG AJ,PAWELETZ CP,et al.A prospective evaluation of circulating tumor cells and cell-free DNA in EGFR mutant non-small cell lung cancer patients treated with erlotinib on a phase Ⅱ trial[J]. Clin Cancer Res,2016. [Epub ahead of print] |
[68] | CHABON JJ,SIMMONS AD,LOVEJOY AF,et al.Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients[J]. Nat Commun,2016,7:11815. |
[69] | THRESS KS,BRANT R,CARR TH,et al.EGFR mutation detection in ctDNA from NSCLC patient plasma:a cross-platform comparison of leading technologies to support the clinical development of AZD9291[J]. Lung Cancer,2015,90(3):509-515. |
[70] | VALADI H,EKSTRO(··)M K,BOSSIOS A,et al. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells[J]. Nat Cell Biol,2007,9(6):654-659. |
[71] | TAKAHASHI K,YAN IK,KOGURE T,et al.Extracellular vesicle-mediated transfer of long non-coding RNA ROR modulates chemosensitivity in human hepatocellular cancer[J]. FEBS Open Bio,2014,4:458-467. |
[72] | ABD ELMAGEED ZY,YANG Y,THOMAS R,et al.Neoplastic reprogramming of patient-derived adipose stem cells by prostate cancer cell-associated exosomes[J]. Stem Cells,2014,32(4):983-997. |
[73] | MELO SA,SUGIMOTO H,O'CONNELL JT,et al. Cancer exosomes perform cell-independent microRNA biogenesis and promote tumorigenesis[J]. Cancer Cell,2014,26(5):707-721. |
[74] | PARK JE,TAN HS,DATTA A,et al.Hypoxic tumor cell modulates its microenvironment to enhance angiogenic and metastatic potential by secretion of proteins and exosomes[J]. Mol Cell Proteomics,2010,9(6):1085-1099. |
[75] | NAZARENKO I,RANA S,BAUMANN A,et al.Cell surface tetraspanin Tspan8 contributes to molecular pathways of exosome-induced endothelial cell activation[J]. Cancer Res,2010,70(4):1668-1678. |
[76] | KHAN S,ASPE JR,ASUMEN MG,et al.Extracellular,cell-permeable survivin inhibits apoptosis while promoting proliferative and metastatic potential[J]. Br J Cancer,2009,100(7):1073-1086. |
[77] | AL-NEDAWI K,MEEHAN B,MICALLEF J,et al.Intercellular transfer of the oncogenic receptor EGFRvIII by microvesicles derived from tumour cells[J]. Nat Cell Biol,2008,10(5):619-624. |
[78] | AGA M,BENTZ GL,RAFFA S,et al.Exosomal HIF1α supports invasive potential of nasopharyngeal carcinoma-associated LMP1-positive exosomes[J]. Oncogene,2014,33(37):4613-4622. |
[79] | OSTENFELD MS,JEPPESEN DK,LAURBERG JR,et al.Cellular disposal of miR23b by RAB27-dependent exosome release is linked to acquisition of metastatic properties[J]. Cancer Res,2014,74(20):5758-5771. |
[80] | YU S,LIU C,SU K,et al.Tumor exosomes inhibit differentiation of bone marrow dendritic cells[J]. J Immunol,2007,178(11):6867-6875. |
[81] | TAYLOR DD,ZACHARIAS W,GERCEL-TAYLOR C.Exosome isolation for proteomic analyses and RNA profiling[J]. Methods Mol Biol,2011,728:235-246. |
[82] | REKKER K,SAARE M,ROOST AM,et al.Comparison of serum exosome isolation methods for microRNA profiling[J]. Clin Biochem,2014,47(1-2):135-138. |
[83] | ALVAREZ ML,KHOSROHEIDARI M,KANCHI RAVI R,et al.Comparison of protein,microRNA,and mRNA yields using different methods of urinary exosome isolation for the discovery of kidney disease biomarkers[J]. Kidney Int,2012,82(9):1024-1032. |
[84] | BARAN J,BAJ-KRZYWORZEKA M,WEGLARCZYK K,et al.Circulating tumour-derived microvesicles in plasma of gastric cancer patients[J]. Cancer Immunol Immunother,2010,59(6):841-850. |
[85] | YAMASHITA T,KAMADA H,KANASAKI S,et al.Epidermal growth factor receptor localized to exosome membranes as a possible biomarker for lung cancer diagnosis[J]. Pharmazie,2013,68(12):969-973. |
[86] | LI Y,ZHANG Y,QIU F,et al.Proteomic identification of exosomal LRG1:a potential urinary biomarker for detecting NSCLC[J]. Electrophoresis,2011,32(15):1976-1983. |
[87] | HU Z,CHEN X,ZHAO Y,et al.Serum microRNA signatures identified in a genome-wide serum microRNA expression profiling predict survival of non-small-cell lung cancer[J]. J Clin Oncol,2010,28(10):1721-1726. |
[88] | CAZZOLI R,BUTTITTA F,DI NICOLA M,et al.microRNAs derived from circulating exosomes as noninvasive biomarkers for screening and diagnosing lung cancer[J]. J Thorac Oncol,2013,8(9):1156-1162. |
[89] | RODRÍGUEZ M,SILVA J,LÓPEZ-ALFONSO A,et al. Different exosome cargo from plasma/bronchoalveolar lavage in non-small-cell lung cancer[J]. Genes Chromosomes Cancer,2014,53(9):713-724. |
[1] | 周韵斓, 沈立松. 液体活检标志物在非小细胞肺癌中的临床应用和挑战[J]. 检验医学, 2023, 38(9): 807-811. |
[2] | 陈颖, 李伟, 林涛, 杨丽. PFTK1表达与非小细胞肺癌微血管密度和患者预后的关系[J]. 检验医学, 2023, 38(7): 634-639. |
[3] | 杨忠信, 李晓宇, 陈涛, 曹文军. IL-8和MMP-2在非小细胞肺癌患者胸腔镜肺段切除术预后评估中的价值[J]. 检验医学, 2023, 38(4): 342-346. |
[4] | 宋世伟, 李景武, 林韬, 刘泽宇, 王志强, 孙卫东. GPNMB与非小细胞肺癌患者肿瘤免疫浸润和预后的相关性[J]. 检验医学, 2023, 38(4): 347-351. |
[5] | 陈馨宁, 黄斐, 姜惠琴, 沈敏娜, 潘柏申, 王蓓丽, 郭玮. 非小细胞肺癌患者血浆EGFR基因c.2572_2573delinsAG位点突变1例报道[J]. 检验医学, 2023, 38(10): 1003-1005. |
[6] | 王芮, 李朝燕, 赵爱光. 循环肿瘤DNA检测在胃癌诊疗中的应用现状[J]. 检验医学, 2022, 37(9): 877-881. |
[7] | 蔚芳芳, 赵琪, 杨丽萍, 王臣玉. 乳腺癌患者血液学参数与HER-2表达的关系[J]. 检验医学, 2022, 37(6): 514-517. |
[8] | 陈思, 刘华, 刘鷖雯, 何怡青, 张国良, 杨翠霞, 杜艳, 高锋. 血清HER-2、CD44联合检测在结直肠癌中的临床价值[J]. 检验医学, 2022, 37(4): 336-341. |
[9] | 赵明娜, 张宸梓, 洪秋双, 娄加陶. IL-8/miR-182正反馈调控轴在非小细胞肺癌中的作用机制研究[J]. 检验医学, 2022, 37(4): 349-355. |
[10] | 徐润灏, 邹琛, 曹芸, 陈风, 刘怡菁, 张舒林, 张洁. 早期非小细胞肺癌患者血清氨基酸检测的临床意义[J]. 检验医学, 2022, 37(12): 1157-1163. |
[11] | 茆政, 钱增堃, 应斐, 王昭俐, 肖群, 崔凡. E-Cad、G-17、HER-2与胃癌术后复发风险的相关性[J]. 检验医学, 2022, 37(1): 41-46. |
[12] | 彭焦武, 孙承谋. miR-124a和miR-449a对非小细胞肺癌的诊断价值[J]. 检验医学, 2021, 36(1): 34-38. |
[13] | 王子谨, 张晓膺. 载脂蛋白M在非小细胞肺癌A549细胞增殖、迁移和侵袭中的作用[J]. 检验医学, 2020, 35(9): 937-942. |
[14] | 袁世洋, 刘川, 欧阳晓春, 谢军平, 贺荣芝, 李里香, 邹叶青. 3D数字PCR检测NSCLC患者血浆EGFR T790M基因突变的临床意义[J]. 检验医学, 2020, 35(8): 806-810. |
[15] | 姜文容, 缪应新, 王粟, 王诗雯, 赵虎, 张艳梅. 临床常见干扰因素对ctDNA EGFR T790M突变检测的影响[J]. 检验医学, 2020, 35(5): 399-404. |
阅读次数 | ||||||
全文 |
|
|||||
摘要 |
|
|||||